SMN1 and proximal spinal muscular atrophy: Gene replacement therapy for SMN protein is one of the most direct approaches to treat SMA patients, however the delivery issue has long been an obstacle, because the blood brain barrier (BBB) restricts delivery of therapeutics to the central nervous system (CNS), where an insufficiency of functional SMN has the most severe consequences [7], [8], [9].